AIMEDBIO

• - AimedBio and SK Plasma have signed a co-development and licensing agreement for the ADC candidate AMB303.
• - This marks SK Plasma’s first entry into ADC oncology drug development, expanding its focus into the field of cancer therapeutics for rare and intractable diseases.
• - Under the agreement, AimedBio will provide the lead candidate identified during early discovery, while SK Plasma will lead clinical development and commercialization. 
  
  
  

Link: https://www.pharmnews.com/news/articleView.php?idxno=260898